Summary
The aim of the present study was to evaluate the effect of 3-(5′-hydroxymethyl-2′-furyl)-1-benzylindazole (YC-1) on multidrug resistance. Expression of human P-glycoprotein was assessed by realtime quantitative RT-PCR and western blot. The efflux function of P-glycoprotein was evaluated by rhodamine 123 accumulation and calcein-AM uptake models. The mechanisms of action of YC-1 on different signaling pathways were studied using series of antagonists and the kinetics was also assessed. Cytotoxicity was evaluated by MTT assay. The results demonstrated that increased intracellular accumulation of rhodamine 123 and increased fluorescence of calcein were observed after YC-1 treatment. Furthermore, increased YC-1 concentration resulted in significant decrease in Vmax while KM remained unchanged suggested that YC-1 acted as a noncompetitive inhibitor of P-glycoprotein. Moreover, the inhibition of Pgp efflux function by YC-1 was significantly reversed by NO synthase inhibitor, L-NAME, the sGC inhibitor, ODQ, the PKG inhibitor, Rp-8-Br-PET-cGMPS, and the PKG inhibitor KT5823. In addition, ERK kinase inhibitor PD98059 also significantly restored YC-1 inhibited Pgp efflux function. These results indicated that YC-1 inhibited Pgp efflux via the NO-cGMP-PKG-ERK signaling pathway through noncompetitive inhibition. The present study revealed that YC-1 could be a good candidate for development as a MDR modulator.
Similar content being viewed by others
Abbreviations
- MDR:
-
Multidrug resistance
- YC-1:
-
3-(5_-hydroxymethyl-2_-furyl)-1-benzyl indazole
- sGC:
-
soluble guanylate cyclase
- L-NAME:
-
NG-nitro-L-arginine methyl ester
- ODQ:
-
1H-[1,2,4]oxadiazolo[4,3-α] quinoxalin-1-one
- Rp-8-Br-PET-cGMPS:
-
β-Phenyl-1, N 2-etheno-8-bromoguanosine-3′,5′-cyclic monophosphorothioate, Rp-isomer
- KT5823:
-
(8R,9S,11S)-(−)-2-methyl-9-methoxyl-9-methoxycarbonyl-8-methyl-2,3,9,10-tetrahydro-8,11-epoxy-1H,8H,11H-2,7b,11a-triazadibenzo(a,g)cyclocta9(cde)trinen-1-one
- PD98059:
-
2′-amino-3′-methoxyflavone, NO, nitric oxide
- NOS:
-
Nitric-oxide synthase
- PKG:
-
cGMP-dependent protein kinase
- ERK:
-
Extracellular signal-regulated kinase
References
Rizzi M, Caccia S, Guiso G, Richichi C, Gorter JA, Aronica E et al (2002) Limbic seizures induce P-glycoprotein in rodent brain: functional implications for pharmacoresistance. J Neurosci 22:5833–5839
Sharom FJ (2008) ABC multidrug transporters: structure, function and role in chemoresistance. Pharmacogenomics 9:105–127
van Vliet EA, van Schaik R, Edelbroek PM, Voskuyl RA, Redeker S, Aronica E et al (2007) Region-specific overexpression of P-glycoprotein at the blood-brain barrier affects brain uptake of phenytoin in epileptic rats. J Pharmacol Exp Ther 322:141–147
Wen T, Liu YC, Yang HW, Liu HY, Liu XD, Wang GJ et al (2008) Effect of 21-day exposure of phenobarbital, carbamazepine and phenytoin on P-glycoprotein expression and activity in the rat brain. J Neurol Sci 270:99–106
Loscher W, Potschka H (2005) Drug resistance in brain diseases and the role of drug efflux transporters. Nat Rev Neurosci 6:591–602
Miller DS, Bauer B, Hartz AM (2008) Modulation of P-glycoprotein at the blood-brain barrier: opportunities to improve central nervous system pharmacotherapy. Pharmacol Rev 60:196–209
Hartz AM, Bauer B, Fricker G, Miller DS (2006) Rapid modulation of P-glycoprotein-mediated transport at the blood-brain barrier by tumor necrosis factor-alpha and lipopolysaccharide. Mol Pharmacol 69:462–470
Juliano RL, Ling V (1976) A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 455:152–162
Horio M, Gottesman MM, Pastan I (1988) ATP-dependent transport of vinblastine in vesicles from human multidrug-resistant cells. Proc Natl Acad Sci USA 85:3580–3584
Schinkel AH (1997) The physiological function of drug-transporting P-glycoproteins. Semin Cancer Biol 8:161–170
Cordon-Cardo C, O’Brien JP, Casals D, Rittman-Grauer L, Biedler JL, Melamed MR et al (1989) Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci USA 86:695–698
Rao VV, Dahlheimer JL, Bardgett ME, Snyder AZ, Finch RA, Sartorelli AC et al (1999) Choroid plexus epithelial expression of MDR1 P glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal-fluid drug-permeability barrier. Proc Natl Acad Sci USA 96:3900–3905
Borst P, Evers R, Kool M, Wijnholds J (1999) The multidrug resistance protein family. Biochim Biophys Acta 1461:347–357
Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwarz UI et al (2001) Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 70:189–199
Marzolini C, Paus E, Buclin T, Kim RB (2004) Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther 75:13–33
Sakaeda T, Nakamura T, Okumura K (2003) Pharmacogenetics of MDR1 and its impact on the pharmacokinetics and pharmacodynamics of drugs. Pharmacogenomics 4:397–410
Pekcec A, Unkruer B, Schlichtiger J, Soerensen J, Hartz AM, Bauer B et al (2009) Targeting prostaglandin E2 EP1 receptors prevents seizure-associated P-glycoprotein up-regulation. J Pharmacol Exp Ther 330:939–947
Riganti C, Miraglia E, Viarisio D, Costamagna C, Pescarmona G, Ghigo D et al (2005) Nitric oxide reverts the resistance to doxorubicin in human colon cancer cells by inhibiting the drug efflux. Cancer Res 65:516–525
Riganti C, Orecchia S, Pescarmona G, Betta PG, Ghigo D, Bosia A (2006) Statins revert doxorubicin resistance via nitric oxide in malignant mesothelioma. Int J Cancer 119:17–27
Yamauchi A, Dohgu S, Nishioku T, Shuto H, Naito M, Tsuruo T et al (2007) An inhibitory role of nitric oxide in the dynamic regulation of the blood-brain barrier function. Cell Mol Neurobiol 27:263–270
Nathan C, Xie QW (1994) Regulation of biosynthesis of nitric oxide. J Biol Chem 269:13725–13728
Magrinat G, Mason SN, Shami PJ, Weinberg JB (1992) Nitric oxide modulation of human leukemia cell differentiation and gene expression. Blood 80:1880–1884
Murphy MP (1999) Nitric oxide and cell death. Biochim Biophys Acta 1411:401–414
Chien WL, Liang KC, Teng CM, Kuo SC, Lee FY, Fu WM (2003) Enhancement of long-term potentiation by a potent nitric oxide-guanylyl cyclase activator, 3-(5-hydroxymethyl-2-furyl)-1-benzyl-indazole. Mol Pharmacol 63:1322–1328
Friebe A, Mullershausen F, Smolenski A, Walter U, Schultz G, Koesling D (1998) YC-1 potentiates nitric oxide- and carbon monoxide-induced cyclic GMP effects in human platelets. Mol Pharmacol 54:962–967
Ko FN, Wu CC, Kuo SC, Lee FY, Teng CM (1994) YC-1, a novel activator of platelet guanylate cyclase. Blood 84:4226–4233
Mulsch A, Bauersachs J, Schafer A, Stasch JP, Kast R, Busse R (1997) Effect of YC-1, an NO-independent, superoxide-sensitive stimulator of soluble guanylyl cyclase, on smooth muscle responsiveness to nitrovasodilators. Br J Pharmacol 120:681–689
Wu CC, Ko FN, Kuo SC, Lee FY, Teng CM (1995) YC-1 inhibited human platelet aggregation through NO-independent activation of soluble guanylate cyclase. Br J Pharmacol 116:1973–1978
Liu YN, Pan SL, Peng CY, Guh JH, Huang DM, Chang YL et al (2006) YC-1 [3-(5′-hydroxymethyl-2′-furyl)-1-benzyl indazole] inhibits neointima formation in balloon-injured rat carotid through suppression of expressions and activities of matrix metalloproteinases 2 and 9. J Pharmacol Exp Ther 316:35–41
Tulis DA, Bohl Masters KS, Lipke EA, Schiesser RL, Evans AJ, Peyton KJ et al (2002) YC-1-mediated vascular protection through inhibition of smooth muscle cell proliferation and platelet function. Biochem Biophys Res Commun 291:1014–1021
Wu CH, Chang WC, Chang GY, Kuo SC, Teng CM (2004) The inhibitory mechanism of YC-1, a benzyl indazole, on smooth muscle cell proliferation: an in vitro and in vivo study. J Pharmacol Sci 94:252–260
Chun YS, Yeo EJ, Park JW (2004) Versatile pharmacological actions of YC-1: anti-platelet to anticancer. Cancer Lett 207:1–7
Pan SL, Guh JH, Chang YL, Kuo SC, Lee FY, Teng CM (2004) YC-1 prevents sodium nitroprusside-mediated apoptosis in vascular smooth muscle cells. Cardiovasc Res 61:152–158
Jamroziak K, Robak T (2004) Pharmacogenomics of MDR1/ABCB1 gene: the influence on risk and clinical outcome of haematological malignancies. Hematology 9:91–105
Ottaiano A, De Chiara A, Fazioli F, Talamanca AA, Mori S, Botti G et al (2005) Biological prognostic factors in adult soft tissue sarcomas. Anticancer Res 25:4519–4526
Tan B, Piwnica-Worms D, Ratner L (2000) Multidrug resistance transporters and modulation. Curr Opin Oncol 12:450–458
Wu SY, Pan SL, Chen TH, Liao CH, Huang DY, Guh JH et al (2008) YC-1 induces apoptosis of human renal carcinoma A498 cells in vitro and in vivo through activation of the JNK pathway. Br J Pharmacol 155:505–513
Sun HL, Liu YN, Huang YT, Pan SL, Huang DY, Guh JH et al (2007) YC-1 inhibits HIF-1 expression in prostate cancer cells: contribution of Akt/NF-kappaB signaling to HIF-1alpha accumulation during hypoxia. Oncogene 26:3941–3951
Shin DH, Kim JH, Jung YJ, Kim KE, Jeong JM, Chun YS et al (2007) Preclinical evaluation of YC-1, a HIF inhibitor, for the prevention of tumor spreading. Cancer Lett 255:107–116
Hurst RD, Azam S, Hurst A, Clark JB (2001) Nitric-oxide-induced inhibition of glyceraldehyde-3-phosphate dehydrogenase may mediate reduced endothelial cell monolayer integrity in an in vitro model blood-brain barrier. Brain Res 894:181–188
Lu DY, Tang CH, Liou HC, Teng CM, Jeng KC, Kuo SC et al (2007) YC-1 attenuates LPS-induced proinflammatory responses and activation of nuclear factor-kappaB in microglia. Br J Pharmacol 151:396–405
Lau CK, Yang ZF, Lam CT, Tam KH, Poon RT, Fan ST (2006) Suppression of hypoxia inducible factor-1alpha (HIF-1alpha) by YC-1 is dependent on murine double minute 2 (Mdm2). Biochem Biophys Res Commun 348:1443–1448
Huang YT, Pan SL, Guh JH, Chang YL, Lee FY, Kuo SC et al (2005) YC-1 suppresses constitutive nuclear factor-kappaB activation and induces apoptosis in human prostate cancer cells. Mol Cancer Ther 4:1628–1635
Lee SJ, Kim YJ, Lee CS, Bae J (2009) Combined application of camptothecin and the guanylate cyclase activator YC-1: impact on cell death and apoptosis-related proteins in ovarian carcinoma cell lines. Chem Biol Interact 181:185–192
Wohlfart P, Malinski T, Ruetten H, Schindler U, Linz W, Schoenafinger K et al (1999) Release of nitric oxide from endothelial cells stimulated by YC-1, an activator of soluble guanylyl cyclase. Br J Pharmacol 128:1316–1322
Liu XM, Peyton KJ, Mendelev NN, Wang H, Tulis DA, Durante W (2009) YC-1 stimulates the expression of gaseous monoxide-generating enzymes in vascular smooth muscle cells. Mol Pharmacol 75:208–217
Modok S, Mellor HR, Callaghan R (2006) Modulation of multidrug resistance efflux pump activity to overcome chemoresistance in cancer. Curr Opin Pharmacol 6:350–354
Wang RB, Kuo CL, Lien LL, Lien EJ (2003) Structure-activity relationship: analyses of p-glycoprotein substrates and inhibitors. J Clin Pharm Ther 28:203–228
Dai CL, Liang YJ, Chen LM, Zhang X, Deng WJ, Su XD et al (2009) Sensitization of ABCB1 overexpressing cells to chemotherapeutic agents by FG020326 via binding to ABCB1 and inhibiting its function. Biochem Pharmacol 78:355–364
Acknowledgments
We acknowledged Dr. Kazumitsu Ueda (Kyoto University) for providing the human MDR1 cDNA. This work was supported grants from National Science Council of Taiwan (NSC 98-2320-B-039-002).
Conflicts of interest
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hung, CC., Liou, HH. YC-1, a novel potential anticancer agent, inhibit multidrug-resistant protein via cGMP-dependent pathway. Invest New Drugs 29, 1337–1346 (2011). https://doi.org/10.1007/s10637-010-9496-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10637-010-9496-1